TITLE

Anticoagulation experts assess practical effects of new heparin potency assay

AUTHOR(S)
Thompson, Cheryl A.
PUB. DATE
November 2009
SOURCE
American Journal of Health-System Pharmacy;11/15/2009, Vol. 66 Issue 22, p1970
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article reports on the consideration of pharmacists William E. Dager and Ann K. Wittwosky to the practical effects of a 10% reduced potency for heparin products in the U.S. It is said that the deliberation on the potency of heparin is caused by the announcement of Food & Drug Authority (FDA) that clinicians should consider the potential for up to a 10% estimated decrease in heparin. It is stated that the announcement was declared by John K. Jenkins, director of FDA's Office of New Drugs.
ACCESSION #
47608264

 

Related Articles

  • FDA CHANGES STANDARD FOR HEPARIN POTENCY.  // Materials Management in Health Care;Nov2009, Vol. 18 Issue 11, p5 

    The article reports that the U.S. Food and Drug Administration has implemented changes on the standard for heparin. It states that the changes has resulted in a ten percent decrease of the drugs potency. It notes that makers of heparin are required to place an 'N' next to the lot number which...

  • FDA Eyes Dosage Limit for Simvastatin.  // Chain Drug Review;7/18/2011, Vol. 33 Issue 12, p94 

    The article reports that the U.S. Food and Drug Administration (FDA) has recommended to reduce the high doses of Merck & Co.'s cholesterol-lowering drug simvastatin or Zocor.

  • Zone in on: INGREDIENTS. Haigney, Susan // Pharmaceutical Technology;Mar2008, Vol. 32 Issue 3, p31 

    The article reports on the production of an active ingredient, used in Baxter International Inc.'s recalled heparin drug, at a manufacturing plant in China. The U.S. Food and Drug Administration revealed the news on February 2008, but noted that the significant role of the ingredient is yet to...

  • FDA officials admit they inspected wrong heparin plant. Tanne, Janice Hopkins // BMJ: British Medical Journal (International Edition);2/23/2008, Vol. 336 Issue 7641, p412 

    The article focuses on a public statement which was issued by the U.S. Food and Drug Administration. In the statement the administration indicated that it inspected the wrong heparin plant when investigating a recall of multidose vials of heparin which was linked to four deaths and 350 reports...

  • The search continues.  // Pharmaceutical Representative;Apr2008, Vol. 38 Issue 4, p12 

    The article reports on the investigation conducted by the U.S. and China on the blood-thinner heparin which has been linked to 19 deaths in the U.S. The Food and Drug Administration (FDA) has widened its investigation into hundreds of reported adverse reactions that have been linked to Baxter...

  • What you don't know will hurt you.  // Nature Biotechnology;Jun2008, Vol. 26 Issue 6, p589 

    This article discusses the problems that led to the tainted heparin that caused over 80 deaths and hundreds of serious adverse events and the response by the U.S. Food and Drug Administration (FDA). An investigation showed that serious miscues by the FDA and the manufacturers led to the tainted...

  • Heparin-Linked Deaths.  // Critical Care Nurse;Jun2008, Vol. 28 Issue 3, p11 

    The article reports on deaths associated with heparin in the U.S. Baxter Healthcare Corp. recalled all its products from the market with heparin because of reported deaths and adverse reactions linked with the use of heparin. The U.S. Food & Drug Administration (FDA) stated that the...

  • The challenges of determining noninferiority margins: a case study of noninferiority randomized controlled trials of novel oral anticoagulants. Wangge, Grace; Roes, Kit C. B.; de Boer, Anthonius; Hoes, Arno W.; Knol, Mirjam J. // CMAJ: Canadian Medical Association Journal;2/19/2013, Vol. 185 Issue 3, p222 

    The article focuses on the fixed margin method for determining a noninferiority margin, as outlined in the draft of the U.S. Food and Drug Administration (FDA). It discusses a case study which aims to determine the effectiveness of thrombin inhibitors and direct inhibitors of factor Xa (DXAIs)....

  • Cash infusion. Conn, Joseph // Modern Healthcare;6/16/2008, Vol. 38 Issue 24, p8 

    The article reports on the plan by the administration of U.S. President George W. Bush to boost the funding of the U.S. Food and Drug Administration (FDA). The Bush administration will ask Congress for an additional $275 million in fiscal 2009 for more workers, programs and technology and the...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics